GeneDx (WGS) AGM 2026 summary

Opening remarks and agenda

• Meeting held virtually to increase inclusivity and reach more stockholders.

• Board members and officers introduced, including CEO, CFO, and auditor from Ernst & Young LLP.

• Meeting agenda included business review, formal proposals, and Q&A session.

Financial performance review

• Reported $427.5 million in revenue for 2025, representing 41% year-over-year growth.

• Achieved 71% adjusted gross margin and $41.8 million in adjusted net income.

• Received FDA Breakthrough Device designation for ExomeDx and GenomeDx tests.

Strategic initiatives and plans

• Focus on expanding exome and genome testing utilization and optimizing unit economics.

• Actively expanding into new markets, including general pediatrics, to enable earlier diagnoses.

• Leveraging data resources and partnerships to drive future opportunities in biopharma.

• SAVES-Kids study highlighted $80,000 average savings per patient per year post-diagnosis.